Comparison of the Early Effects of Brimonidine and Apraclonidine as Topical Ocular Hypotensive Agents

Todd L. Maus, MD; Cherie Nau; Richard F. Brubaker, MD

Objective: To compare the mechanism of action of short-term administration of brimonidine tartrate and apraclonidine hydrochloride as topical ocular hypotensive agents.

Subjects and Methods: Two randomized, double-masked, placebo-controlled studies of 19 normal human subjects were carried out. The first study compared brimonidine with apraclonidine in timolol maleate–treated eyes, and the second study compared latanoprost with placebo in timolol-treated eyes. The rate of aqueous flow and intraocular pressure were measured in both studies. The topical drug combinations were instilled the night before and repeated the morning before the measurements. Aqueous humor flow was measured by the rate of disappearance of topically applied fluorescein. Intraocular pressure was measured by pneumatonometry every 2 hours from 8:15 AM to 4:15 PM.

Results: Both brimonidine and apraclonidine further reduced aqueous flow in timolol-treated eyes from $1.23 \pm 0.21 \mu L/min$ to $0.96 \pm 0.16 \mu L/min$ and $0.98 \pm 0.17 \mu L/min$, respectively. Consistent reductions were observed in intraocular pressure, with average reductions of 19% with brimonidine and 17% with apraclonidine. Latanoprost had no effect on aqueous flow in timolol-treated eyes ($P = .15$), but showed an average reduction in intraocular pressure of 13%.

Conclusions: Brimonidine and apraclonidine are similar in their effects on the aqueous system. Both reduce intraocular pressure in the timolol-treated eye, primarily, if not exclusively, by further suppressing aqueous flow. In contrast, latanoprost reduces intraocular pressure in the timolol-treated eye without affecting aqueous flow.

SUBJECTS AND METHODS

Twenty normal human volunteers were recruited, of whom 19 met all entry criteria and participated in 2 randomized, double-masked, placebo-controlled studies. The first study was a direct comparison of apraclonidine treatment in one eye vs brimonidine treatment in the other eye when both eyes were concurrently treated with timolol. The second study was a comparison of latanoprost treatment in one eye vs placebo treatment in the other eye when both eyes were concurrently treated with timolol. All subjects completed both studies; for each subject, the second study was carried out 2 weeks or longer after the first.

Each subject underwent a baseline history and ocular examination to gather data and to determine eligibility. Exclusion criteria included pregnancy or breastfeeding, long-term use of eye medications, allergy to ocular medications, history of a major illness or notable eye disease, use of systemic medications known to affect aqueous humor dynamics, and recent participation as a volunteer in another medical study. Subjects were also excluded specifically for any of the following: intraocular pressure in either eye outside the inclusive range of 10 to 20 mm Hg, asymmetry of intraocular pressures greater than 3 mm Hg, obvious asymmetry of eyes, pigment dispersion, pseudoxefoliation, ametropia greater than 5 diopters, narrow angles, or any feature of the eyelids, cornea, or anterior chamber that would interfere with the accuracy of tonometry or fluorophotometry. All eligible subjects underwent the written informed consent procedure monitored by the institutional review board of the Mayo Foundation, Rochester, Minn.

The 4 drugs used in the study were obtained from commercial suppliers: 0.3% apraclonidine hydrochloride (Iopidine; Alcon Laboratories), 0.2% brimonidine tartrate (Alphagan; Allergan), 0.005% latanoprost (Xalatan; Pharmacia, Kalamazoo, Mich), and 0.5% timolol maleate (Timoptic; Merck & Co, West Point, Pa). The placebo was an artificial tear solution (Hypotears; IOLab, Claremont, Calif). All products except timolol were repackaged and relabeled by a pharmacist. All repackaged containers were identical and were labeled according to study number (1 or 2), according to eye (left or right), and according to subject number (1-19). The right and left eyes of all subjects for study 1 were randomized between brimonidine and apraclonidine. The right and left eyes of all subjects for study 2 were randomized between latanoprost and placebo.

All drug instillations were carried out by one of us (C.N.). For each study, 1 drop of timolol was instilled into each eye at 3 PM the day before the measurement of aqueous flow and intraocular pressure. Five minutes after instillation of timolol, the assigned drug from the masked container for each eye was instilled according to the labeled instructions. Subjects were allowed to blot each eye with separate tissues and then asked to close their eyes for 2 minutes after drug instillation and warned not to touch either eye so as not to transfer drug from one eye to the other.

At 2 AM during the night before the measurement of aqueous flow and intraocular pressure, each subject awakened and instilled 2% fluorescein sodium (Alcon Laboratories) into each eye several times to produce a depot of fluorescein in the cornea for measurement of aqueous humor flow the following day.

At 7:30 AM on the day of the measurements, timolol was instilled again into each eye. At 8 AM, the assigned drugs from the masked containers were instilled once again. Beginning at 8:15 AM and every 2 hours thereafter until 4:15 PM, the fluorescence in the cornea and anterior chamber was measured in each eye by fluorophotometry. Immediately after each measurement of fluorescence, 0.5% proparacaine hydrochloride (Alcaine; Alcon Laboratories) was instilled into each eye and intraocular pressures were measured with a pneumatonometer (Mentor O&O, Norwell, Mass). Three measurements were taken of the right eye followed by 3 measurements of the left eye. The intraocular pressure was recorded as the mean of the 3 measurements. The pneumatonometer tip was cleaned with an alcohol swab and allowed to dry between right and left eye measurements.

Aqueous humor flow was calculated from the fluorescence measurements and from measurements of the volume of the anterior chamber as described previously. The variable apparent resistance to outflow (R) was calculated for each eye from the relation R = intraocular pressure/aqueous flow. After completion of the study and tabulation of all data, the code was broken and the data were stratified by drug. The statistical analysis was carried out by making comparisons with a paired Student t test. A 2-sided test was used. A P value of less than .05 was considered significant.

Uveoscleral outflow is difficult to measure in human subjects, and the precision and accuracy of the methods have not been established. Despite these difficulties, it is accepted that latanoprost's mechanism of action is to enhance outflow of aqueous humor. This acceptance is based on the observation that latanoprost lowers intraocular pressure in humans without producing any measurable change in tonographic facility of outflow or in the rate of aqueous humor flow. Whether brimonidine has uveoscleral outflow effects, however, is more difficult to demonstrate, since it has effects on flow and intraocular pressure that are comparable with those of apraclonidine and timolol, neither of which is thought to affect outflow.

The simplest way of determining if brimonidine but not apraclonidine has outflow effects would be to com-
pare them in eyes that have been pretreated with an aqueous suppressant, such as timolol. In this way, the aqueous-suppressing effects of both drugs would be blunted, and the stage would be set to observe any differences in their effects on intraocular pressure that could be attributed to outflow effects. To determine if the experimental procedure has sufficient sensitivity to measure such an outflow effect, one must simply test the experimental procedure with a known uveoscleral enhancer, such as latanoprost. This reasoning was the basis for the experiment described in this report.

**RESULTS**

Timolol reduced the intraocular pressure, compared with the baseline examination, at all times that were tested. The pressure in the placebo-treated eyes before the administration of timolol was 15.4 ± 2.5 mm Hg (mean ± SD). After administration of timolol and artificial tears, the intraocular pressure was found to be lower at each measurement from 8:15 AM to 4:15 PM (all P < .001). Compared with the baseline examination, the intraocular pressure was reduced at all times in the eyes treated with timolol in combination with each of the 3 ocular hypotensive drugs (all P < .001) (Figure).

The flow of aqueous humor from 8:15 AM to 4:15 PM in the timolol- and placebo-treated eyes was 1.23 ± 0.21 µL/min, consistent with the well-known flow-suppressing effect of timolol. The addition of apraclonidine to timolol suppressed the aqueous flow an additional 20% to 0.98 ± 0.17 µL/min (P = .001). The addition of brimonidine to timolol suppressed the aqueous flow an additional 22% to 0.96 ± 0.16 µL/min (P = .002). The addition of latanoprost to timolol had no statistically significant effect on aqueous humor flow (P = .15) (Table 1). Both apraclonidine and brimonidine in combination with timolol suppressed aqueous flow more than latanoprost and timolol, but there was no difference between the aqueous flow in eyes treated with apraclonidine and timolol and that in eyes treated with brimonidine and timolol (P = .60).

The intraocular pressure was lowered by the addition of each drug to timolol at all times tested. Compared with timolol alone, latanoprost lowered intraocular pressure 13% from 10:15 AM to 4:15 PM (P < .001). Apraclonidine lowered intraocular pressure 17% (P = .002) and brimonidine lowered it 19% (P = .001) compared with timolol alone (Table 2). There was no difference in the timolol-treated eyes in the ocular hypotensive effect of apraclonidine compared with latanoprost (P = .24), of brimonidine compared with latanoprost (P = .16), or of brimonidine compared with apraclonidine (P = .31).

Apparent resistance to outflow was lowered by latanoprost from 10.6 ± 2.3 mm Hg · min · µL⁻¹ to 9.0 ± 2.3 mm Hg · min · µL⁻¹ (P < .001), as expected from its known action as an outflow-enhancing drug (Table 3). Neither apraclonidine nor brimonidine changed the apparent resistance compared with placebo but had higher apparent resistance compared with latanoprost, the demonstration drug for an outflow effect. No difference in apparent resistance was observed between apraclonidine and brimonidine.

**COMMENT**

Initial studies of the acute effect of timolol demonstrated its flow-suppressing effect. In a recent study, Schadlu et al found the rate of aqueous flow in a group of untreated normal volunteers under conditions identical to those of the current study to be 2.26 ± 0.49 µL/min. In that same study, apraclonidine reduced the flow to 1.39 ± 0.34 µL/min and brimonidine reduced the flow to 1.24 ± 0.28 µL/min. In the current study, the rate of aqueous humor flow when timolol only was administered was 1.23 ± 0.21 µL/min. Thus, timolol, apraclonidine, and brimonidine each acting alone produce suppressions of flow of 1.03 µL/min, 0.87 µL/min, and 1.02 µL/min, respectively, and appear to be equally efficacious in this effect. These findings are similar to what was found by Koskela and Brubaker, where apraclonidine suppressed aqueous flow by 0.84 ± 0.61 µL/min and where...
the effects of timolol and apraclonidine on flow were not significantly different.

The addition of either apraclonidine or brimonidine to timolol caused further suppression of aqueous humor flow. Apraclonidine caused an additional 0.25-µL/min suppression and brimonidine caused an additional 0.27-µL/min suppression. Thus, neither drug appears to be superior to the other as a suppressor of aqueous humor flow either in untreated eyes or in timolol-treated eyes.

The additional effect on flow is approximately one fourth the effect that the 2-α₂-adrenergic agonists have when acting on the untreated eye. In a previous study, a single drop of apraclonidine was administered to normal human volunteers 4 hours after treatment with timolol, and the investigators were unable to demonstrate any additional effect of apraclonidine on aqueous humor flow. However, in long-term timolol users, apraclonidine did have an additional suppressing effect similar to what was observed in this study.

Apaclonidine and brimonidine each caused a small but significant lowering of intraocular pressure in the timolol-treated eye of approximately 2 mm Hg, representing 17% to 19% lowering. This is comparable with the results of Stewart and coworkers, who found an additional 10% to 22% lowering of intraocular pressure when apraclonidine was added to the timolol-treated eye. The change in intraocular pressure in the current study was consistent with the additional suppression of aqueous humor flow without invoking an effect on any other measure of aqueous humor dynamics. Latanoprost also lowered intraocular pressure approximately 2 mm Hg, but without any additional suppression of aqueous flow. Latanoprost’s effect therefore must be attributed to an effect on outflow, an effect that is consistent with previous studies of its mechanism of ocular hypotension.

The magnitude of this effect in our volunteers was somewhat lower than what has been observed when latanoprost has been added to the regimen of patients with glaucoma receiving long-term treatment with aqueous suppressors, including β-adrenergic antagonists and carbonic anhydrase inhibitors. Alm et al found a 30% additional decrease, whereas Diestelhorst et al found a 25% decrease, Khouri et al found a greater than 15% increase in 13 of 18 patients, and Seong et al found a 23% decrease. The effect that we measured, although smaller, was nonetheless consistent and easy to measure despite the fact that the intraocular pressure of these subjects was very low.

In 1972 Barány et al and later Reiss and Brubaker, introduced the concept of apparent resistance to outflow to study the nonlinearity of outflow resistance. Apparent resistance is simply the intraocular pressure divided by the rate of aqueous outflow from the eye. This measure of aqueous dynamics can be calculated simply and reliably for any eye when the rate of aqueous humor flow through the anterior chamber and the intraocular pressure are known. Knowing the apparent resistance sheds no light on the pathway that aqueous humor might take on its way to the heart. However, the apparent resistance will change in predictable ways when the eye is acted on by an ocular hypotensive drug. If the drug suppresses aqueous humor flow, apparent resistance will increase; if the drug enhances outflow via any pathway, it will decrease. This relationship can be seen in Table 4, a compilation of calculations from previous studies in which flow and pressure were measured by the same techniques reported in this study.

In a recent study comparing apraclonidine and brimonidine in normal eyes receiving no concurrent treatment, apraclonidine was found to increase apparent resistance from 5.9 ± 1.8 mm Hg · min · µL⁻¹ to 7.9 ± 3.0 mm Hg · min · µL⁻¹ (P = .01) and brimonidine increased it from 6.1 ± 2.0 mm Hg · min · µL⁻¹ to 8.1 ± 2.5 mm Hg · min · µL⁻¹ (P = .008) (Table 4). No difference in

Table 2. Intraocular Pressure, Average, 10:15 AM to 4:15 PM*

<table>
<thead>
<tr>
<th>Intraocular Pressure, Mean ± SD, mm Hg</th>
<th>% Difference (Probability)</th>
<th>Placebo</th>
<th>Latanoprost</th>
<th>Apraclonidine hydrochloride</th>
<th>Brimonidine tartrate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>12.6 ± 1.8</td>
<td>...†</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Latanoprost</td>
<td>11.0 ± 1.3</td>
<td>−13 (&lt;.001)</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Apraclonidine hydrochloride</td>
<td>10.4 ± 1.5</td>
<td>−17 (.002)</td>
<td>−5 (.24)</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Brimonidine tartrate</td>
<td>10.2 ± 1.8</td>
<td>−19 (.001)</td>
<td>−7 (.16)</td>
<td>−2 (.31)</td>
<td></td>
</tr>
</tbody>
</table>

*All eyes treated with timolol maleate.
†Ellipses indicate not applicable.

Table 3. Apparent Resistance (Intraocular Pressure/Flow)*

<table>
<thead>
<tr>
<th>Apparent Resistance, Mean ± SD, mm Hg · min · µL⁻¹</th>
<th>% Difference (Probability)</th>
<th>Placebo</th>
<th>Latanoprost</th>
<th>Apraclonidine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>10.6 ± 2.3</td>
<td>...†</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Latanoprost</td>
<td>9.0 ± 2.3</td>
<td>−15 (&lt;.001)</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Apraclonidine hydrochloride</td>
<td>11.1 ± 2.9</td>
<td>5 (.52)</td>
<td>23 (.005)</td>
<td>...</td>
</tr>
<tr>
<td>Brimonidine tartrate</td>
<td>11.0 ± 3.2</td>
<td>4 (.55)</td>
<td>22 (.005)</td>
<td>−1 (.92)</td>
</tr>
</tbody>
</table>

*All eyes treated with timolol maleate.
†Ellipses indicate not applicable.
apparent resistance was observed between the 2 drugs ($P = .60$). The effect on resistance was similar to that of other drugs that are believed to be pure aqueous flow suppressors (Table 4). In the current study, the use of timolol reduced the aqueous-suppressing effects of these drugs, and the increase in apparent resistance was not significant. However, the use of timolol should have unmasked an outflow effect or differences in an outflow effect between the 2 drugs if one but not the other had such an effect. In contrast to latanoprost, no such effect should have done before the notion is accepted that brimonidine has clinically significant effects on aqueous humor outflow in contrast to apraclonidine.

What remains to be done is to carry out a similar study in patients with ocular hypertension and glaucoma with longer exposure to the drugs. These additional studies should be done before the notion is accepted that brimonidine has clinically significant effects on aqueous humor outflow in contrast to apraclonidine.

Accepted for publication November 17, 1998.

This study was supported in part by grant EY 00634 from the National Eye Institute, National Institutes of Health, Bethesda, Md; an unrestricted grant from Research to Prevent Blindness Inc, New York, NY; the Bonner Foundation, Princeton, NJ; and the Mayo Foundation, Rochester, Minn.

Reprints: Richard F. Brubaker, MD, Mayo Clinic, 200 First St SW, Rochester, MN 55905.

REFERENCES